A Monte Carlo investigation of the dose distribution for new I-125 Low Dose Rate brachytherapy source in water and in different media

• Autorzy: Fardi Zeinab , Taherparvar Payvand

Identyfikatory

DOI

10.2478/pjmpe-2019-0003

• Języki publikacji: EN

Abstrakty

EN

Permanent and temporary implantation of I-125 brachytherapy sources has become an official method for the treatment of different cancers. In this technique, it is essential to determine dose distribution around the brachytherapy source to choose the optimal treatment plan. In this study, the dosimetric parameters for a new interstitial brachytherapy source I-125 (IrSeed-125) were calculated with GATE/GEANT4 Monte Carlo code. Dose rate constant, radial dose function and 2D anisotropy function were calculated inside a water phantom (based on the recommendations of TG-43U1 protocol), and inside several tissue phantoms around the IrSeed-125 capsule. Acquired results were compared with MCNP simulation and experimental data. The dose rate constant of IrSeed-125 in the water phantom was about 1.038 cGy·h⁻¹U⁻¹ that shows good consistency with the experimental data. The radial dose function at 0.5, 0.9, 1.8, 3 and 7 cm radial distances were obtained as 1.095, 1.019, 0.826, 0.605, and 0.188, respectively. The results of the IrSeed-125 is not only in good agreement with those calculated by other simulation with MCNP code but also are closer to the experimental results. Discrepancies in the estimation of dose around IrSeed-125 capsule in the muscle and fat tissue phantoms are greater than the breast and lung phantoms in comparison with the water phantom. Results show that GATE/GEANT4 Monte Carlo code produces accurate results for dosimetric parameters of the IrSeed-125 LDR brachytherapy source with choosing the appropriate physics list. There are some differences in the dose calculation in the tissue phantoms in comparison with water phantom, especially in long distances from the source center, which may cause errors in the estimation of dose around brachytherapy sources that are not taken account by the TG43-U1 formalism.

Słowa kluczowe

EN

brachytherapy; dosimetric parameters; TG-43U1; IrSeed-125; Monte Carlo

• Wydawca: Polskie Towarzystwo Fizyki Medycznej ; De Gruyter
• Czasopismo: Polish Journal of Medical Physics and Engineering
• Rocznik: 2019
• Tom: Vol. 25, Iss. 1
• Strony: 15--22
• Opis fizyczny: Bibliogr. 25 poz., rys., tab.

Twórcy

autor

Fardi Zeinab

• Department of Physics, Faculty of Science, University of Guilan, 4193833697, Rasht

autor

Taherparvar Payvand

• Department of Physics, Faculty of Science, University of Guilan, 4193833697, Rasht

Bibliografia

• [1] Russell KJ, Blasko JC. Recent advances in interstitial brachytherapy for localized prostate cancer. in: Therapeutic strategies in prostate cancer. Problems in urology series. Vol. 7. 4th edition. J. B. Lippincott Co, Philadelphia; 1993: 260-278.
• [2] Ghiassi-Nejad M, Jafarizadeh M, Ahmadian-Pour MR, Ghahramani AR. Dosimetric characteristics of 192Ir sources used in interstitial brachytherapy. Appl Radiat Isot. 2001;55(2):189-195.
• [3] Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22(2):209-234.
• [4] Heintz BH, Wallace RE, Hevezi JM. Comparison of I-125 sources used for permanent interstitial implants. Med Phys. 2001;28(4):671-682.
• [5] Rivard MJ, Butler WM, DeWerd LA, et al. Supplement to the 2004 update of the AAPM Task Group No. 43 Report. Med Phys. 2007;34(6):2187-2205.
• [6] Solberg TD, DeMarco JJ, Hugo G, Wallace RE. Dosimetric parameters of three new solid core I-125 brachytherapy source. J Appl Clin Med Phys. 2002;3(2):119-134.
• [7] Wallace RE. Dosimetric characterization of a new 125Iodine brachytherapy source, model I125-SL. Proceedings of the 22nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (Cat. No.00CH37143), Chicago, IL, 2000, pp. 376-379 vol.1.
• [8] Lohrabian V, Sheibani S, Aghamiri MR, et al. Determination of Dosimetric Characteristics of IrSeed I-125 Brachytherapy Source. Iran J Med Phys. 2013;10(3):109-117.
• [9] Forster RA, Cox LJ, Barrett RF, et al. MCNP Version 5. Nucl Instrum Meth Phys Res B. 2004;213:82-86.
• [10] Rajabi R, Taherparvar P. Monte Carlo dosimetry for a new 32P brachytherapy source using FLUKA code. J Contemp Brachytherapy. 2019. doi:10.5114/jcb.2019.83002.
• [11] Thiam CO, Breton V, Donnarieix D, Habib B, et al. Validation of a dose deposited by low-energy photons using GATE/GEANT4. Phys Med Biol. 2008;53(11):3039-3055.
• [12] Agostinelli S, Allison J, Amako K, et al. Geant4 - a simulation toolkit. Nucl Instrum Meth A. 2003;506(3):250-303.
• [13] Nelson WR, Hirayama H, Rogers DWO. The EGS4 code system, Report SLAC-265. Stanford Linear Accelerator Center, Stanford, CA, USA, 1985.
• [14] Meigooni AS, Yoe-Sein MM, Al-Otoom AY, Sowards KT. Determination of the dosimetric characteristics of InterSource125 Iodine brachytherapy source. Appl Radiat Isot. 2001;56(4):589-599.
• [15] Rodríguez EAV, Alcón EPQ, Rodriguez ML, et al. Dosimetric parameters estimation using PENELOPE MonteCarlo simulation code: Model 6711 a I-125 brachytherapy seed. Appl Radiat Isot. 2005;63(1):41-48.
• [16] Rivard MJ. Monte Carlo radiation dose simulations and dosimetric comparison of the model 6711 and 9011 I-125 brachytherapy sources. Med Phys. 2009;36(2):486-491.
• [17] Baghani HR, Lohrabian V, Aghamiri MR, Robatjazi M. Monte Carlo Determination of Dosimetric Parameters of a New I-125 Brachytherapy Source According to AAPM TG-43 (U1) Protocol. Arch Iran Med. 2016;19(3):186-191.
• [18] Rivard MJ, Corsey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med. Phys. 2004;31(3):633-674.
• [19] Taherparvar P, Sadremomtaz A. Development of GATE Monte Carlo simulation for a CsI pixelated gamma camera dedicated to high resolution animal SPECT. Australas Phys Eng Sci Med. 2018;41:31-38.
• [20] NCRP. A handbook of radioactivity measurements procedures; NCRP Report No. 58. Bethesda: National Council on Radiation Protection and Measurements, 1985.
• [21] Badry H, Oufni L, Ouabi H, Hirayama H. A Monte Carlo investigation of the dose distribution for 60Co high dose rate brachytherapy source in water and in different media. Appl Radiat Isot. 2018;136:104-110.
• [22] Ghorbani M, Salahshour F, Haghparast A, et al. Effect of tissue composition on dose distribution in brachytherapy with various photon emitting sources. J Contemp Brachytherapy. 2014;6(1):54-67.
• [23] International Commission on Radiation Units and Measurements, 1989. Tissue Substitutes in Radiation Dosimetry and Measurement. ICRU Report no. 44. Bethesda, MD.
• [24] Sowards KT, Meigooni AS. A Monte Carlo evaluation of the dosimetric characteristics of the Bests Model 2301 125I brachytherapy source. Appl Radiat Isot. 2002;57(3):327-333.
• [25] Meigooni AS, Gearheart DM, Sowards K. Experimental determination of dosimetric characteristics of Best® 125I brachytherapy source. Med Phys. 2000;27(9):2168-2173.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).